Anti-NASH Drug Development Hitches a Lift on PPAR Agonism

Non-alcoholic fatty liver disease (NAFLD) affects one-third of the population worldwide, of which a substantial number of patients suffer from non-alcoholic steatohepatitis (NASH). NASH is a severe condition characterized by steatosis and concomitant liver inflammation and fibrosis, for which no dru...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cells
Autores principales: Boeckmans, Joost, Natale, Alessandra, Rombaut, Matthias, Buyl, Karolien, Rogiers, Vera, De Kock, Joery, Vanhaecke, Tamara, Rodrigues, Robim M.
Formato: Artigo
Lenguaje:Inglês
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7016963/
https://ncbi.nlm.nih.gov/pubmed/31877771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells9010037
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares